'Long acting' diaporamas de présentation

Nashat H. Rabadi,MD FCCP

Nashat H. Rabadi,MD FCCP. Pulmonary and Critical Care Medicine Buffalo Medical Group PC Associate Clinical Professor State University of New York at Buffalo Chief of Pulmonary and Critical Care Medicine Sisters of Charity Hospital. Impact of COPD in the US.

1.38k views • 114 slides

COPD: Reversing the Reversible in 2014

COPD: Reversing the Reversible in 2014. Donald M. Pell M. D., FCCP. Introduction. Prevalence 5.9% of U.S. population or about 24,000,000 adults (ATS Gold Paper 2004) In 2000 there were 122,000 deaths (CDC data) For the first time more women than men

875 views • 76 slides

Asthma, Bronchiolitis, and Pnemonia Tintinalli Chapt 123-124. April 18th 2005 Mark Rodkey, M.D., FAAP Scott Gunderon, D.

Asthma, Bronchiolitis, and Pnemonia Tintinalli Chapt 123-124. April 18th 2005 Mark Rodkey, M.D., FAAP Scott Gunderon, D.O. Asthma. Chronic disease of the tracheobronchial tree characterized by airway obstruction, inflammation, hyperresponsiveness, mucous plugging and edema.

1.14k views • 64 slides

1.13k views • 60 slides

GP Practice Update

GP Practice Update. Lynn Orford Community Respiratory Team and HOSAR Lead. Spirometry. Guidelines published by the PCC in 2013 National recommendation for Diagnostic Spirometry to be quality assured come into effect 2020. Equipment. A spirometer that meets the correct industry standard

1.38k views • 54 slides

Contraceptive update

Contraceptive update. Dr Christine Roke National Medical Advisor, Family Planning March 2012. Long Acting Reversible Contraception - LARC . New emphasis because: Easier to use - action less often than monthly Increased efficacy - all less than 1% failure rate.

838 views • 53 slides

BZD & ? -drug ? ????????

1.39k views • 53 slides

Sympathomimetics in Bronchial asthma

Sympathomimetics in Bronchial asthma. Presented by :Heba Abd El-fattah Sabry. Asthma-Treatment What are the treatments? Drugs that reduce inflammation Drugs that reduce bronchoconstriction. Asthma - Introduction (Cont.). ? Airway Inflammation. ? Bronchospasm. Drug therapy.

870 views • 49 slides

553 views • 47 slides

Insulin Therapy and GLP-1 analogues

Insulin Therapy and GLP-1 analogues. Dr. Spurgeon Dept of Endocrinology, Christian Medical College, Vellore. 100. 80. 60. ? -cell function ( % ). 40. 20. 0. -12. -6. 0. 6. 12. Years. Progressive Beta Cell failure in Type II Diabetes Mellitus.

742 views • 45 slides

Opioid Risk:Benefit Issues

Opioid Risk:Benefit Issues. U.S. Food and Drug Administration Anesthetic and Life Support Drugs Advisory Committee Bethesda MD September 9. 2003 Arthur G. Lipman, PharmD Professor of Pharmacotherapy, College of Pharmacy Director of Clinical Pharmacology, Pain Management Center

666 views • 35 slides

COPD in 2009

COPD in 2009. Perspective of Respiratory Physicians Ramesh Kaul, MD M. Surgery FCCP. Speaker disclosure. Presently Speaker for Astra Zeneca( Symbicort) Previous speaker for GlaxoSmithKline (Advair) Previous speaker for Boeringer Inghelheim (Spiriva , Atrovent)

533 views • 35 slides

In the name of GOD

In the name of GOD. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes A meta-analysis. Sara Sadri. case scenario.

498 views • 34 slides

Diabetic Ketoacidosis

Diabetic Ketoacidosis. Definition. 2009 ADA consensus statement on DKA Life-threatening condition characterized by hyperglycemia (glucose >250mg/dl) Ketonemia or ketonuria Arterial pH <7.3 Bicarb < 15mmol/L. Epidemiology/Statistics. Annual incidence 5-8 episodes/1000 person-years

1.13k views • 34 slides

D- Selection of Antihypertensive Drug

D- Selection of Antihypertensive Drug. Selection of Antihypertensive Drug. Alpha Blocker. AT 1 Antagonist. ? 2 - agonists. ACE Inhibitor. Ganglionic blockers. Dr. Rx Rational. Drug of choice. Beta Blocker. Vasodilators. Ca ++ Antagonist. Diuretic. 1. 2. 3.

592 views • 29 slides

DIABETES MELLITUS Inpatient Management

DIABETES MELLITUS Inpatient Management. Alejandro Gonzalez MD, FACP. Hyperglycemia in hospitalized patients. Associated with: Poor outcomes Prolonged hospitalization Infection Disability after discharge Death.

987 views • 24 slides

Gedefaw Abeje Fekadu ( MPH/RH , PhD candidate) Akinyinka O. Omigbodun , Professor (UI)

Factors associated with long acting and permanent contraceptive methods use in Ethiopia; further analysis of the 2016 DHS data. Gedefaw Abeje Fekadu ( MPH/RH , PhD candidate) Akinyinka O. Omigbodun , Professor (UI) Olumuyiwa A. Roberts (PhD UI)

463 views • 22 slides

PAIN MANAGEMENT

559 views • 22 slides

Anthelmintik

479 views • 14 slides

Long Acting Reversible Contraception (LARC)

Long Acting Reversible Contraception (LARC). By Tess & Michaela . Implant. Effectiveness: <1/1000 pregnancy in 3 years (>99%) What: releasing progesterone, stops ovulation, thickens cervical mucous, thins uterine lining. Lasts: 3 years.

683 views • 6 slides